CMS has adopted a new HCPCS code C9733, effective April 1, for non-ophthalmic fluorescent vascular angiography. CMS indicates the code is used to report SPY ® Fluorescence Vascular Angiography.
CMS also added four new pass-through drugs, effective April 1:
- C9288 (injection, centruroides (scorpion) immune f(ab)2 (equine), 1 vial)
- C9289 (injection, asparaginase erwinia chrysanthemi, 1,000 iu)
- C9290 (injection, bupivacaine liposome, 1 mg)
- C9291 (injection, aflibercept (Eylea), 2mg vial)
Additionally, CMS adjusted payment rates for four drugs for the July 1, 2011–September 30, 2011 timeframe and four drugs for the October 1, 2011–December 31, 2011 timeframe. If providers wish to receive any additional amounts due to the corrected rates, they must request reprocessing of their claims.
The April OPPS transmittal also discusses a new edit for skin substitutes which requires providers report them with certain application procedures (CPT codes 15271–15278) in order to be paid separately. See the transmittal or the I/OCE for the updated list of 27 skin substitute codes. In the special processing logic of the April I/OCE, it makes clear that if the skin substitute codes are reported without one of the application procedure codes, they will be packaged rather than the claim being returned to the provider for correction.
This is actually implementing edits for longstanding, but confusing guidance CMS had given for biologicals that could be used either in an application procedure or implanted during a surgical procedure. As with other implants, when the skin substitute is implanted, it is packaged into the surgical procedure implanting it, but when applied as a skin substitute it is paid separately.
Previously, the guidance relied on hospitals properly reporting the HCPCS codes, and in some cases not reporting a HCPCS code, to ensure separate payment was not made inappropriately. This edit ensures that skin substitute will get packaged appropriately by packaging it whenever the application procedure is not present. This new edit is effective April 1, but providers should review prior claims submission and coding policies to ensure they have been submitting claims appropriately prior to implementation of the new edit.
One final edit that was updated related to cardioverter-defibrillator system implants. Formerly, when CPT code 33249 (Insertion or replacement of permanent pacing cardioverter-defibrillator system with transvenous lead(s), single or dual chamber) was billed there was an edit allowing device code C1882 (Cardioverter-defibrillator, other than single or dual chamber (implantable)). However, due to a January 1 change in the description of the procedure code, this is no longer correct, and CMS is removing the edit effective retroactively to January 1.